Allogene Therapeutics ALLO Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$173.76M+31.1% | -$190.89M+25.9% | -$212.02M+25.2% | -$236.91M+15.2% | -$252.32M+13.7% | ||
| $12.13M-8.0% | $12.36M-9.4% | $12.54M-9.7% | $12.65M-11.3% | $13.18M-7.5% | ||
| $33.74M-35.1% | $37.64M-27.3% | $42.39M-21.7% | $47.12M-16.0% | $51.99M-12.0% | ||
| —— | —— | -$1.83M-118% | -$7.99M-430% | -$755K+91.3% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | -$654K+9.4% | -$3.26M-6,025% | ||
| $1.29M+210% | $1.14M+338% | $901K— | $657K— | $415K— | ||
| -$7.87M-13.6% | -$7.5M-19.0% | -$7.39M-21.4% | -$7.22M— | -$6.93M— | ||
| -$109.23M+44.6% | -$149.25M+25.5% | -$158.35M+27.1% | -$172.77M+24.5% | -$197.33M+13.1% | ||
| $296K-62.3% | $386K-44.4% | $643K+4.0% | $829K+312% | $785K+60.5% | ||
| $189.73M-42.6% | $138.26M-61.8% | $156.85M-59.1% | $297.88M-24.0% | $330.57M-31.8% | ||
| $15.62M— | $0— | —— | —— | —— | ||
| $59.8M— | $95.56M— | $116.88M— | —— | —— | ||
| —— | —— | —— | —— | $11.54M-87.1% | ||
| $37.29M-71.1% | $30.16M-74.2% | $28.04M-74.8% | $25.48M-77.8% | $129.02M+34.9% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$21.63M-193% | $2.72M-87.8% | $2.71M-87.9% | $3.6M-83.2% | $23.19M— | ||
| -$7.87M-13.6% | -$7.5M-19.0% | -$7.39M-21.4% | -$7.22M— | -$6.93M— | ||
| $1.29M+210% | $1.14M+338% | $901K— | $657K— | $415K— | ||
| -$4.99M— | -$3.24M— | —— | —— | —— | ||
| $3.8M-44.6% | $4.22M-49.4% | $5.05M-49.5% | $5.83M-48.2% | $6.86M-32.2% | ||
| $12.93M+2.1% | $12.92M+3.3% | $12.88M+4.4% | $12.85M+5.0% | $12.66M+4.2% | ||
| $249.82M-35.2% | $234.2M-45.8% | $274.38M-41.2% | $322.27M-38.3% | $385.69M-30.8% | ||
| —— | —— | —— | —— | —— | ||
| $4K— | $0— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $279K— | —— | ||
| -$7.87M-13.6% | -$7.5M-19.0% | -$7.39M-21.4% | -$7.22M— | -$6.93M— | ||
| $4.29M-18.1% | $4.36M-17.3% | $4.42M-57.0% | $4.85M-46.0% | $5.24M-31.0% | ||
| -$109.53M+44.7% | -$149.63M+25.6% | -$158.99M+27.0% | -$173.6M+24.2% | -$198.12M+12.9% | ||
| -$109.53M+44.7% | -$149.63M+25.6% | -$158.99M+27.0% | -$173.6M+24.2% | -$198.12M+12.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Allogene Therapeutics generate?
- Allogene Therapeutics (ALLO) generated -$109.2M in operating cash flow over the trailing twelve months.
- What is Allogene Therapeutics's free cash flow?
- After $296.0K of capital expenditures, Allogene Therapeutics's free cash flow was -$109.5M over the trailing twelve months, up 44.7% year over year.
- Where does Allogene Therapeutics's cash flow data come from?
- Every line is extracted from Allogene Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.